Pfizer (PFE)
(Delayed Data from NYSE)
$28.55 USD
-0.21 (-0.73%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $28.59 +0.04 (0.14%) 7:58 PM ET
2-Buy of 5 2
A Value F Growth B Momentum C VGM
Brokerage Reports
Pfizer Inc. [PFE]
Reports for Purchase
Showing records 541 - 560 ( 569 total )
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
3Q Revenue and EPS Ahead of Expectations. Lipitor Patent Expiration Approaching
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
MODEL STOCK PORTFOLIO -CONSERVATIVE GROWTH
Provider: J.J.B. Hilliard, W.L. Lyons
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
First Quarter 2011 Revenue About Even. Non-GAAP EPS Exceeded Consensus Expectations.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Despite Headwinds in the U.S. and Europe, Fourth Quarter Revenue Exceeded Expectations
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Management raises guidance for CY10 & maintains earlier guidance for CY12....
Provider: FIRST GLOBAL
Analyst: THOMAS K